CU20200037A7 - Derivados de indol-2-carboxamidas sustituidos con amino-tiazol activos contra el virus de la hepatitis b (vhb) - Google Patents
Derivados de indol-2-carboxamidas sustituidos con amino-tiazol activos contra el virus de la hepatitis b (vhb)Info
- Publication number
- CU20200037A7 CU20200037A7 CU2020000037A CU20200037A CU20200037A7 CU 20200037 A7 CU20200037 A7 CU 20200037A7 CU 2020000037 A CU2020000037 A CU 2020000037A CU 20200037 A CU20200037 A CU 20200037A CU 20200037 A7 CU20200037 A7 CU 20200037A7
- Authority
- CU
- Cuba
- Prior art keywords
- derivatives
- hbv
- virus
- amino
- indol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
<p>La presente invención se refiere a derivados de indol-2-carboxamidas sustituidos con amino-tiazol de fórmula I</p> <p>ESPACIO PARA LA FÓRMULA</p> <p>los cuales pueden inhibir la proteína o proteínas codificada(s) por el virus de la hepatitis B (VHB) o interferir con la función del ciclo de replicación del VHB, a composiciones que comprenden estos derivados, y a un método para la preparación de dichos derivados.</p>
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17199687 | 2017-11-02 | ||
| PCT/EP2018/000502 WO2019086141A1 (en) | 2017-11-02 | 2018-11-02 | Novel, highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis b virus (hbv) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CU20200037A7 true CU20200037A7 (es) | 2021-03-11 |
Family
ID=60201941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2020000037A CU20200037A7 (es) | 2017-11-02 | 2018-11-02 | Derivados de indol-2-carboxamidas sustituidos con amino-tiazol activos contra el virus de la hepatitis b (vhb) |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US11267825B2 (es) |
| EP (1) | EP3704127A1 (es) |
| JP (1) | JP2021501764A (es) |
| KR (1) | KR20200083551A (es) |
| CN (1) | CN111448199A (es) |
| AR (1) | AR113826A1 (es) |
| AU (1) | AU2018361364B2 (es) |
| BR (1) | BR112020008762A2 (es) |
| CA (1) | CA3081386A1 (es) |
| CL (1) | CL2020001145A1 (es) |
| CU (1) | CU20200037A7 (es) |
| EA (1) | EA202091113A1 (es) |
| EC (1) | ECSP20029558A (es) |
| GE (2) | GEAP202115351A (es) |
| IL (1) | IL274298A (es) |
| MA (1) | MA50524A (es) |
| MX (1) | MX2020004839A (es) |
| PH (1) | PH12020550525A1 (es) |
| SG (1) | SG11202003700TA (es) |
| TW (1) | TW201930315A (es) |
| UY (1) | UY37962A (es) |
| WO (1) | WO2019086141A1 (es) |
| ZA (1) | ZA202002249B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY38436A (es) * | 2018-11-02 | 2020-05-29 | Aicuris Gmbh & Co Kg | Nuevas 6,7-dihidro-4h-pirazolo[1,5-a] pirazinindol-2-carboxamidas activas contra el virus de la hepatitis b (vhb) |
| PY1991601A (es) * | 2018-11-02 | 2020-11-02 | Aicuris Gmbh & Co Kg | Nuevas 6,7-dihidro-4h-pirazolo [1,5-a] pirazina indole-2-carboxamidas activas contra el virus de la hepatitis b (vhb) |
| WO2020221826A1 (en) * | 2019-04-30 | 2020-11-05 | Aicuris Gmbh & Co. Kg | Novel indole-2-carboxamides active against the hepatitis b virus (hbv) |
| WO2021118727A2 (en) * | 2019-11-08 | 2021-06-17 | President And Fellows Of Harvard College | Fluorogenic amino acids |
| KR20230124583A (ko) | 2020-11-23 | 2023-08-25 | 이난타 파마슈티칼스, 인코포레이티드 | 신규한 스피로피롤리딘 유래 항바이러스제 |
| WO2022235605A1 (en) | 2021-05-04 | 2022-11-10 | Enanta Pharmaceuticals, Inc. | Novel macrocyclic antiviral agents |
| US11858945B2 (en) | 2021-11-12 | 2024-01-02 | Enanta Pharmaceuticals, Inc. | Alkyne-containing antiviral agents |
| US11919910B2 (en) | 2021-11-12 | 2024-03-05 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| US11912714B2 (en) | 2021-11-12 | 2024-02-27 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| US11993600B2 (en) | 2021-12-08 | 2024-05-28 | Enanta Pharmaceuticals, Inc. | Saturated spirocyclics as antiviral agents |
| US12006291B2 (en) | 2022-01-11 | 2024-06-11 | Enanta Pharmaceuticals, Inc. | Processes for the preparation of 4,6,7-trifluoro-1H-indole-2-carboxylic acid |
| US12145942B2 (en) | 2022-04-05 | 2024-11-19 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| CN116068100A (zh) * | 2022-11-24 | 2023-05-05 | 上海研诺医药科技有限公司 | 一种测定4-羟乙基哌嗪乙磺酸的检测方法 |
| CN116396204B (zh) * | 2023-03-29 | 2024-09-24 | 无锡科华生物科技有限公司 | 一种4,6,7-三氟-1h-吲哚-2-羧酸的制备方法 |
| CN117886810B (zh) * | 2023-12-18 | 2026-04-07 | 徐州医科大学 | 一种吲哚啉类化合物及其制备方法和应用 |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0973778A1 (en) | 1997-03-07 | 2000-01-26 | Novo Nordisk A/S | 4,5,6,7-TETRAHYDRO-THIENO 3,2-c]PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE |
| DE19817264A1 (de) | 1998-04-18 | 1999-10-21 | Bayer Ag | Neue Dihydropyrimidine |
| WO2000058302A1 (de) | 1999-03-25 | 2000-10-05 | Bayer Aktiengesellschaft | Dihydropyrimidine und ihre verwendung zur behandlung von hepatitis b |
| WO2001045712A1 (de) | 1999-12-22 | 2001-06-28 | Bayer Aktiengesellschaft | Arzneimittelkombinationen gegen virale erkrankungen |
| DE10012823A1 (de) | 2000-03-16 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
| CA2773066A1 (en) | 2003-11-12 | 2005-05-26 | Daiichi Sankyo Company, Limited | Process for producing thiazole derivative |
| WO2006033995A2 (en) | 2004-09-16 | 2006-03-30 | Valeant Research And Development | Thiazolidin-4-ones having anti-hepatitis b activity |
| JP2009531314A (ja) | 2006-03-10 | 2009-09-03 | ニューロジェン・コーポレーション | ピペラジニルオキソアルキルテトラヒドロイソキノリン類および関連類似物 |
| TW200833333A (en) | 2007-01-12 | 2008-08-16 | Astrazeneca Ab | New pyridine analogues |
| EP2300437B1 (en) | 2008-06-05 | 2013-11-20 | Glaxo Group Limited | Benzpyrazol derivatives as inhibitors of pi3 kinases |
| US8024013B2 (en) | 2008-07-09 | 2011-09-20 | Sony Ericsson Mobile Communications Ab | Regulating power duty cycle of an RF transmitter/receiver responsive to distance moved |
| EP2327704A4 (en) | 2008-08-29 | 2012-05-09 | Shionogi & Co | RING-CONDENSED AZOL DERIVATIVE WITH PI3K-INHIBITING EFFECT |
| US20120029190A1 (en) | 2009-04-03 | 2012-02-02 | Douglas Burdi | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
| CA2806103A1 (en) * | 2010-08-31 | 2012-03-08 | Vanderbilt University | Bicyclic oxazole and thiazole compounds and their use as allosteric modulators of mglur5 receptors |
| AU2010360038B2 (en) | 2010-09-02 | 2014-05-15 | Suven Life Sciences Limited | Heterocyclyl compounds as Histamine H3 receptor ligands |
| US9334256B2 (en) | 2011-06-15 | 2016-05-10 | Nono Inc. | Agents and methods for treating ischemic and other diseases |
| JP5977347B2 (ja) | 2011-07-01 | 2016-08-24 | バルーク エス．ブルームバーグ インスティテュート | Ｈｂｖ感染に対する抗ウイルス剤としてのスルファモイルベンズアミド誘導体 |
| GEP201706656B (en) | 2011-11-11 | 2017-04-25 | Pfizer | 2-thiopyrimidinones |
| KR101939710B1 (ko) | 2011-12-21 | 2019-01-17 | 노비라 테라퓨틱스, 인코포레이티드 | B형 간염의 항바이러스성 제제 |
| AU2013207205B2 (en) | 2012-01-06 | 2017-02-02 | Janssen Sciences Ireland Uc | 4,4-disubstituted-1,4-dihydropyrimidines and the use thereof as medicaments for the treatment of Hepatitis B |
| UY34993A (es) | 2012-08-28 | 2014-02-28 | Janssen R & D Ireland | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b |
| CN104797561B (zh) | 2012-08-28 | 2017-03-01 | 爱尔兰詹森科学公司 | 稠合二环的氨磺酰基衍生物及其作为药物用于治疗乙型肝炎的用途 |
| EP2945623B1 (en) | 2013-01-15 | 2018-09-05 | Suzhou Kintor Pharmaceuticals, Inc. | Hedgehog pathway signaling inhibitors and therapeutic applications thereof |
| US8993771B2 (en) | 2013-03-12 | 2015-03-31 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
| HRP20181863T1 (hr) | 2013-05-17 | 2018-12-28 | Janssen Sciences Ireland Uc | Derivati sulfamoiltiofenamida i njihova uporaba kao lijekova za liječenje hepatitisa b |
| EA201592126A1 (ru) | 2013-05-17 | 2016-05-31 | Ф. Хоффманн-Ля Рош Аг | 6-мостиковые гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b |
| NO3024819T3 (es) | 2013-07-25 | 2018-07-21 | ||
| ES2739435T3 (es) | 2013-10-18 | 2020-01-31 | Univ Indiana Res & Tech Corp | Efectores del ensamblaje viral de la hepatitis B |
| HK1223094A1 (zh) | 2013-11-14 | 2017-07-21 | Novira Therapeutics Inc. | 氮杂环庚烷衍生物和治疗乙型肝炎感染的方法 |
| US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| ES2714110T3 (es) | 2014-03-07 | 2019-05-27 | Hoffmann La Roche | Heteroarildihidropirimidinas 6-fusionadas novedosas para el tratamiento y profilaxis de la infección por el virus de la hepatitis B |
| CN110437153A (zh) | 2014-03-13 | 2019-11-12 | 美国印第安纳大学研究和技术公司 | 乙型肝炎核心蛋白变构调节剂 |
| US9771358B2 (en) | 2014-03-28 | 2017-09-26 | Sunshine Lake Pharma Co., Ltd. | Dihydropyrimidine compounds and their application in pharmaceuticals |
| EP3139954A4 (en) | 2014-05-09 | 2018-02-28 | Indiana University Research and Technology Corporation | Methods and compositions for treating hepatitis b virus infections |
| CN106573898B (zh) | 2014-08-14 | 2018-11-09 | 豪夫迈·罗氏有限公司 | 治疗和预防乙型肝炎病毒感染的新的哒嗪酮和三嗪酮 |
| ES2802412T3 (es) | 2014-12-02 | 2021-01-19 | Novira Therapeutics Inc | Compuestos de sulfonamida inversa a base de sulfuro, alquilo y piridilo para el tratamiento del VHB |
| US9527845B2 (en) | 2014-12-30 | 2016-12-27 | Novira Therapeutics, Inc. | Derivatives and methods of treating hepatitis B infections |
| MA41338B1 (fr) | 2015-01-16 | 2019-07-31 | Hoffmann La Roche | Composés de pyrazine pour le traitement de maladies infectieuses |
| SG11201706835WA (en) | 2015-03-16 | 2017-09-28 | Hoffmann La Roche | Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor |
| WO2016149401A2 (en) * | 2015-03-18 | 2016-09-22 | Abide Therapeutics, Inc. | Piperazine carbamates and methods of making and using same |
| US10442788B2 (en) | 2015-04-01 | 2019-10-15 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| EP3292120B1 (en) | 2015-05-04 | 2019-06-19 | H. Hoffnabb-La Roche Ag | Tetrahydropyridopyrimidines and tetrahydropyridopyridines as inhibitors of hbsag (hbv surface antigen) and hbv dna production for the treatment of hepatitis b virus infections |
| WO2016183266A1 (en) | 2015-05-13 | 2016-11-17 | Enanta Pharmaceuticals, Inc. | Ehpatitis b antiviral agents |
| US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| US10179131B2 (en) | 2015-07-13 | 2019-01-15 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| CN107849037B (zh) | 2015-07-21 | 2020-04-17 | 豪夫迈·罗氏有限公司 | 用于治疗和预防乙型肝炎病毒感染的三环4-吡啶酮-3-甲酸衍生物 |
| WO2017015451A1 (en) | 2015-07-22 | 2017-01-26 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| TWI721016B (zh) | 2015-09-15 | 2021-03-11 | 美商艾森伯利生物科學公司 | B型肝炎核心蛋白質調節劑 |
| CN108430971A (zh) | 2015-09-29 | 2018-08-21 | 诺维拉治疗公司 | 乙型肝炎抗病毒剂的晶体形式 |
| WO2017076286A1 (zh) | 2015-11-04 | 2017-05-11 | 南京明德新药研发股份有限公司 | 二氢吡啶并环化合物的晶型、制备方法和中间体 |
| US10280175B2 (en) | 2016-02-02 | 2019-05-07 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| KR102398439B1 (ko) | 2016-03-07 | 2022-05-16 | 이난타 파마슈티칼스, 인코포레이티드 | B형 간염 항바이러스제 |
| EP3458455B1 (en) | 2016-05-20 | 2021-06-16 | F. Hoffmann-La Roche AG | Novel pyrazine compounds with oxygen, sulfur and nitrogen linker for the treatment of infectious diseases |
| WO2018011160A1 (en) | 2016-07-14 | 2018-01-18 | F. Hoffmann-La Roche Ag | 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases |
| EP3484885B1 (en) | 2016-07-14 | 2020-03-04 | H. Hoffnabb-La Roche Ag | Carboxy 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases |
| JP7051804B2 (ja) | 2016-07-14 | 2022-04-11 | エフ．ホフマン－ラ ロシュ アーゲー | 感染症の治療のための６，７－ジヒドロ－４Ｈ－ピラゾロ［１，５－ａ］ピラジン化合物と６，７－ジヒドロ－４Ｈ－トリアゾロ［１，５－ａ］ピラジン化合物 |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| WO2018052967A1 (en) | 2016-09-13 | 2018-03-22 | Arbutus Biopharma, Inc. | Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same |
| JOP20190105A1 (ar) * | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| AU2018227811A1 (en) | 2017-03-02 | 2019-09-19 | Assembly Biosciences, Inc. | Cyclic sulfamide compounds and methods of using same |
| US11098010B2 (en) | 2017-03-21 | 2021-08-24 | Arbutus Biopharma Corporation | Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same |
| BR112020008765A2 (pt) * | 2017-11-02 | 2020-10-20 | Aicuris Gmbh & Co. Kg | indol-2-carboxamidas pirazolo-piperidina substituídas altamente ativas inovadoras ativas contra o vírus da hepatite b (hbv) |
-
2018
- 2018-11-02 GE GEAP202115351A patent/GEAP202115351A/en unknown
- 2018-11-02 TW TW107139067A patent/TW201930315A/zh unknown
- 2018-11-02 AU AU2018361364A patent/AU2018361364B2/en not_active Ceased
- 2018-11-02 CU CU2020000037A patent/CU20200037A7/es unknown
- 2018-11-02 SG SG11202003700TA patent/SG11202003700TA/en unknown
- 2018-11-02 JP JP2020524457A patent/JP2021501764A/ja active Pending
- 2018-11-02 CA CA3081386A patent/CA3081386A1/en not_active Abandoned
- 2018-11-02 GE GEAP201815351A patent/GEP20227373B/en unknown
- 2018-11-02 US US16/761,189 patent/US11267825B2/en not_active Expired - Fee Related
- 2018-11-02 EP EP18811439.1A patent/EP3704127A1/en not_active Withdrawn
- 2018-11-02 MX MX2020004839A patent/MX2020004839A/es unknown
- 2018-11-02 AR ARP180103202A patent/AR113826A1/es unknown
- 2018-11-02 KR KR1020207015662A patent/KR20200083551A/ko not_active Ceased
- 2018-11-02 WO PCT/EP2018/000502 patent/WO2019086141A1/en not_active Ceased
- 2018-11-02 MA MA050524A patent/MA50524A/fr unknown
- 2018-11-02 BR BR112020008762-9A patent/BR112020008762A2/pt not_active IP Right Cessation
- 2018-11-02 CN CN201880079554.1A patent/CN111448199A/zh active Pending
- 2018-11-02 EA EA202091113A patent/EA202091113A1/ru unknown
- 2018-11-05 UY UY0001037962A patent/UY37962A/es not_active Application Discontinuation
-
2020
- 2020-04-27 IL IL274298A patent/IL274298A/en unknown
- 2020-04-30 CL CL2020001145A patent/CL2020001145A1/es unknown
- 2020-04-30 PH PH12020550525A patent/PH12020550525A1/en unknown
- 2020-05-04 ZA ZA2020/02249A patent/ZA202002249B/en unknown
- 2020-06-01 EC ECSENADI202029558A patent/ECSP20029558A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018361364B2 (en) | 2020-11-26 |
| GEAP202115351A (en) | 2021-12-10 |
| ZA202002249B (en) | 2022-01-26 |
| EP3704127A1 (en) | 2020-09-09 |
| US11267825B2 (en) | 2022-03-08 |
| AU2018361364A1 (en) | 2020-05-21 |
| MA50524A (fr) | 2020-09-09 |
| IL274298A (en) | 2020-06-30 |
| MX2020004839A (es) | 2020-10-16 |
| US20200354379A1 (en) | 2020-11-12 |
| WO2019086141A1 (en) | 2019-05-09 |
| BR112020008762A2 (pt) | 2020-10-20 |
| ECSP20029558A (es) | 2020-07-31 |
| PH12020550525A1 (en) | 2021-04-26 |
| EA202091113A1 (ru) | 2020-08-28 |
| WO2019086141A8 (en) | 2019-08-29 |
| JP2021501764A (ja) | 2021-01-21 |
| UY37962A (es) | 2019-05-31 |
| KR20200083551A (ko) | 2020-07-08 |
| CN111448199A (zh) | 2020-07-24 |
| CA3081386A1 (en) | 2019-05-09 |
| SG11202003700TA (en) | 2020-05-28 |
| TW201930315A (zh) | 2019-08-01 |
| CL2020001145A1 (es) | 2020-10-09 |
| AR113826A1 (es) | 2020-06-17 |
| GEP20227373B (en) | 2022-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU20200045A7 (es) | Derivados de indol-2-carboxamidas sustituidos con pirazolo-piperidina activos contra el virus de la hepatitis b (vhb) | |
| CL2020001145A1 (es) | Nuevas indol-2-carboxamidas sustituidas con amino-tiazol, de alta actividad, activas contra el virus de la hepatitis b (vhb). | |
| CU20210038A7 (es) | Compuestos derivados sustituidos de 6,7-dihidro- 4h-pirazolo pirazinindol-2' carboxamidas activas contra el virus de la hepatitis b (vhb) | |
| CL2017001798A1 (es) | Compuestos de pirazina para el tratamiento de enfermedades infecciosas. | |
| CL2020000487A1 (es) | Agentes antivirales contra la hepatitis b. | |
| CO2019000069A2 (es) | Agentes antivirales contra la hepatitis b | |
| CL2018001207A1 (es) | Compuesto de 7-(tiazol-5-il)pirrolopirimidina como agonista de tlr7 | |
| UY37997A (es) | Agentes antivirales contra la hepatitis b | |
| BR112018071678A2 (pt) | compostos terapêuticos úteis para o tratamento profilático ou terapêutico de uma infecção por vírus hiv | |
| EA201890735A1 (ru) | Модуляторы корового белка вируса гепатита b | |
| CL2016000493A1 (es) | Inhibidores de polimerasa hcv. | |
| CL2016002179A1 (es) | Nuevas heteroarildihidropirimidinas 6-fusionadas para el tratamiento y la profilaxis de la infección por virus de la hepatitis b. | |
| CL2015003615A1 (es) | Nucleósidos sustituidos, nucleótidos y análogos de los mismos. | |
| GT201300093A (es) | Compuestos antivirales | |
| EA201791903A1 (ru) | β-D-2'-ДЕЗОКСИ-2'-α-ФТОР-2'-β-C-ЗАМЕЩЕННЫЕ-2-МОДИФИЦИРОВАННЫЕ-N6-ЗАМЕЩЕННЫЕ ПУРИНОВЫЕ НУКЛЕОТИДЫ ДЛЯ ЛЕЧЕНИЯ ВЫЗВАННЫХ HCV ЗАБОЛЕВАНИЙ | |
| CU20210088A7 (es) | Compuestos derivados sustituidos de indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb) | |
| EA201592184A1 (ru) | 4'-фтор-2'-метилзамещенные нуклеозидные производные | |
| MX2017011655A (es) | Compuestos de aza-piridona y usos de estos. | |
| CL2015001971A1 (es) | Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas. | |
| MX381896B (es) | Compuestos de tiazolida para el tratamiento de infecciones virales. | |
| CL2017000152A1 (es) | Derivados de isoindolinona | |
| CU20210037A7 (es) | Compuestos derivados sustituidos de urea 6,7-dihidro-4h-pirazolo [1,5-a] pirazinas activas contra el virus de la hepatitis b (vhb) | |
| CL2015003358A1 (es) | Compuestos derivados de nucleósidos 4'-azido-3'-desoxi-3'-fluoro sustituidos; composición farmacéutica que comprende a dichos compuestos y el uso de los mismos para tratar una infección del virus de la hepatitis c (hcv). | |
| UY37166A (es) | Nucleósidos ánalogos de alquinilo como inhibidores de rinovirus humano | |
| EA201790778A1 (ru) | Фармацевтические композиции длительного действия от гепатита с |